4-Methylcyclohexane-1-peroxol | 92454-93-8

• 分子结构分类: 有机化合物 - 有机氧化合物 - 有机氢过氧化物
• 英文名称: 4-Methylcyclohexane-1-peroxol
• 英文别名: 1-hydroperoxy-4-methylcyclohexane
• CAS: 92454-93-8
• 化学式: C₇H₁₄O₂
• 分子量: 130.18
• InChiKey: LRJUVXUZTKFWRL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Cyclohexyl GPR40 agonists for the treatment of type II diabetes
  申请人：Janssen Pharmaceutica NV

  公开号：US10988433B2

  公开（公告）日：2021-04-27

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, A, W, L, Ra, and G are defined herein: and by Formula (II) as follows: wherein R1B, WB, LB, , and GB are defined herein.

  公开了用于治疗受 GPR40 受体调节影响的疾病的化合物、组合物和方法。此类化合物由如下式（I）表示： 其中 R1、R2、R3、A、W、L、Ra 和 G 在本文中定义： 及式（II）如下 其中 R1B、WB、LB 和 GB 的定义见本文。
• CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES
  申请人：Janssen Pharmaceutica NV

  公开号：US20200039914A1

  公开（公告）日：2020-02-06

  Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R 1 , R 2 , R 3 , A, W, L, R a , and G are defined herein: and by Formula (II) as follows: wherein R 1B , W B , L B , , and G B are defined herein.
• US3956397A
  申请人：——

  公开号：US3956397A

  公开（公告）日：1976-05-11
• US4169115A
  申请人：——

  公开号：US4169115A

  公开（公告）日：1979-09-25
• [EN] MIXED STEROIDAL 1,2,4,5-TETRAOXANE COMPOUNDS AND METHODS OF MAKING AND USING THEREOF<br/>[FR] COMPOSES MELANGES DE STEROIDES 1,2,4,5-TETRAOXANE ET PROCEDES DE FABRICATION ASSOCIES
  申请人：US ARMY MED RES MAT COMMAND

  公开号：WO2003068736A2

  公开（公告）日：2003-08-21

  Disclosed herein are mixed steroidal tetraoxanes having the following structural Formula (I), wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or ethyl; R3 is H, methyl, or ethyl; R4 is H, methyl, ethyl, tert-butyl, phenyl, p-hydroxyphenyl, p-methoxyphenyl, or p-nitrophenyl, or Formula (a), wherein Y is C1-C4 straight or branched-chain alkoxy, or Formula (b), wherein W is N, R5 is hydrogen, methyl, ethyl, or n-propyl, isopropyl, or methyl ethanoate 2-yl, and R6 is hydrogen, methyl, ethyl, or n-propyl, or R5 and R6 are part of a pyrrolidine or piperidine ring; X is a C1-C4 straight or branched-chain alkoxy, a primary amino, a N-akylamino wherein the alkyl is a straight-chain alkyl groups containing from 1 to 4 carbon atoms, methyl ethanoate-2-yl, N-phenylamino, p-nitrophenyl, N,N-dimethylamino, N,N-diethylamino, N,N-di(n-propyl)amino, N-pyrrolidino, or N-piperidino as single compounds, and any mixture of all possible stereoisomers at C(4’’). n may be 0, 1, 2, or 3, and methods of making and using thereof. As disclosed herein, the mixed steroidal tetraoxanes of the present invention exhibit antimalarial, antibacterial, and antiproliferative activity. Thus, as disclosed herein, the mixed steroidal tetraoxanes of the present invention may be used to treat, prevent, or inhibit malaria, bacterial infections, and diseases and disorders associated with cell proliferation in a subject.